United Kingdom· GB-APID-31143911000001106
Blincyto 38.5micrograms powder for concentrate and solution for solution for infusion vials
A medicinal product containing blinatumomab, registered in United Kingdom by Amgen Ltd.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Blinatumomab
- Manufacturer
- Amgen Ltd
- Country
- United Kingdom (GB)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 3
- gtin8715131009922
- gtin08715131023706
- gtin8715131023706
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Blinatumomab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlincytoParanova Oy
- NorwayBlincytoAmgen Europe B.V.
- BelgiumBlincyto 38.5 µgAmgen Europe
- PolandBlincytoAmgen Europe B.V.
- SwedenBLINCYTO 38,5 mikrogram Pulver till koncentrat och lösning till infusionsvätska, lösningAmgen Europe B.V.
- IrelandBLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Europe B.V.,
- SpainBlincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusionAmgen Europe B.V.
- SwitzerlandBlincyto
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Blincyto
- Norway · Blincyto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a4356388-1b82-406f-8870-b2ece8c3c5a5 GET /v1/drugs/a4356388-1b82-406f-8870-b2ece8c3c5a5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "31143911000001106",
"desc": "Blincyto 38.5micrograms powder for concentrate and solution for solution for infusion vials (Amgen Ltd)",
"form": "Powder and solution for solution for infusion",
"vpid": "31143811000001101",
"source": "dmd",
"vtm_id": "778531003",
"strength": "38.5 microgram",
"substance": "Blinatumomab",
"ingredient": "Blinatumomab",
"supplier_code": "3303701000001100"
}See everything about blinatumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.